Cancer drug design targeted by COSMIC's new 3D system

Collaboration between Wellcome Trust Sanger Institute and Astex Pharmaceuticals brings together COSMIC (Catalogue of Somatic Mutations In Cancer) and wwPDB (worldwide Protein Data Bank) to visualise genomic and proteomic data on cancer mutations

Cancer drug design targeted by COSMIC's new 3D system

TP53 mutant hotspots around DNA.png
TP53 molecule around DNA, showing hotspots of mutation, as displayed by COSMIC-3D

COSMIC-3D, the most comprehensive system for exploring cancer mutations in three dimensions, is launched today by COSMIC, based at the Wellcome Trust Sanger Institute, in collaboration with Astex Pharmaceuticals, Cambridge, UK. With extensive colourful and helpful visualisations, the new resource can help identify and characterise drug targets as well as support the design of new therapeutics for cancer.

The new tool is set to change the way researchers interact with genomic mutations in order to identify new cancer drug targets.

Available at http://cancer.sanger.ac.uk/cosmic3d, COSMIC-3D provides interactive 3D visualisations of more than 8,000 human proteins displaying cancer mutations. It enables researchers to develop a clearer understanding of which mutations are implicated in cancer progression, and how these mutations impact molecular structure and function.

Significantly, COSMIC-3D displays known and predicted drug binding sites within the protein structure. This displays cancer mutations alongside binding sites with predictions of how likely a pocket is to be successful as a drug target, enhancing the exploration and identification of how mutations impact therapeutic targets.

COSMIC-3D has been designed to directly assist pharmaceutical development. The new resource utilises COSMIC - Catalogue of Somatic Mutations in Cancer, the world’s largest expert-curated human cancer mutation database - and also incorporates structural information from the Worldwide Protein Data Bank (wwPDB).

“Combining cancer genomics data from COSMIC with the human structural proteome provides valuable insights into how cancer mutations affect molecular functions and impact cancer progression. This will enable scientists to better tackle the challenges of developing cancer-specific therapeutics.”

Dr Marcel Verdonk, Senior Director at Astex Pharmaceuticals

“This is a hugely exciting addition to the COSMIC family, COSMIC-3D will allow researchers to explore cancer mutations in a completely new way, providing new perspective for precision medicine.”

Dr Simon Forbes, Head of COSMIC at the Wellcome Trust Sanger Institute

Notes to Editors
Selected Websites
Is cancer a genetic disease?FactsIs cancer a genetic disease?
Cancer is the most common human genetic disease. The transition from a normal cell to a malignant cancer is driven by changes to a cell’s DNA, also known as mutations.

My career in genomics: cancer biologyVideoMy career in genomics: cancer biology
In this film Niki Patel talks about her research looking at the genetics of cancer. This is one of a series of films providing a unique insight into different careers in the field of genomics.

BRAF: From Gene to Cancer TherapyActivitiesBRAF: From Gene to Cancer Therapy
Take on the role of a genome researcher and look at real cancer DNA datasets, taken from cancer patients, to find areas of mutation in the BRAF gene.

Contact the Press Office

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Emily Mobley, Media Officer

Tel +44 (0)1223 496 851

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7900 607793

Recent News

Wellcome Sanger Institute calls for the free movement of scientists across European borders following Brexit

The Institute has provided evidence for the UK Government Science and Technology Committee’s inquiry into an immigration system that works for science and innovation

Genomics offers new treatment options for infants with range of soft tissue tumours

Scientists uncover the genetic changes causing a group of related infant cancers

Genetic discovery will help clinicians identify aggressive versus benign bone tumours

A genetic change affecting the transcription factor, FOS is specific to osteoblastoma, distinguishing it from osteosarcoma